Search | Clinical Trials Finder

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: interleukin 2, rhuMAb; Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 34
States / cities: La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more

Conditions: Lymphoma, Non-Hodgkin, MALT Lymphoma
Interventions: Fludarabine, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, New York

Conditions: Healthy Volunteers
Interventions: CKD-510 capsule (reference), CKD-510 tablet (test); Drug
Lead sponsor: Chong Kun Dang Pharmaceutical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glycemia
Interventions: Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Post Surgical Pain
Interventions: 2mg Dexamethasone, 4mg Dexamethasone, Ropivacaine (TAP blocks), Morphine, Bupivacaine Hydrochloride, Normal saline 1ml, Normal saline 0.5ml; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Mild Traumatic Brain Injury (mTBI)
Interventions: Symptom-Targeted Approach to Rehabilitation for Concussion; Behavioral
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Wahiawa, Hawaii • San Antonio, Texas

Conditions: Positron-Emission Tomography, Metastatic Solid Tumors
Interventions: ⁸⁹Zr-Df-IAB22M2C; Drug
Lead sponsor: ImaginAb, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more

Conditions: Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions: Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis; Biological · Drug · Procedure
Lead sponsor: Macarena De La Fuente, MD; Other
Eligibility: 13 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bacteremia
Interventions: DSTA4637S, Placebo, SOC; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more

Conditions: Hyperkalemia
Interventions: LOKELMA 5 GM Powder for Oral Suspension; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more

Conditions: Prostate Cancer
Interventions: 89Zr-DFO-huJ591; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HNSCC, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Tobacco-Related Carcinoma, Carcinoma in Situ, Dysplasia, Hyperplasia, Premalignant Lesion
Interventions: Avmacol®; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Bladder Cancer, Melanoma
Interventions: Nivolumab, Nivolumab plus Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Farmington, Connecticut • Middletown, New Jersey • Harrison, New York + 2 more

Conditions: Status Asthmaticus
Interventions: Montelukast Oral Granules, Albuterol, Corticosteroid; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 4 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lymphoma, B-cell Lymphoma
Interventions: Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 10 more

Conditions: Sarcopenia, Hypogonadism, Muscular Diseases
Interventions: Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation); Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Neoplasm
Interventions: MK-8294, CD8 PET Tracer; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Chicago, Illinois • Hackensack, New Jersey • Houston, Texas

Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions: Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements; Drug
Lead sponsor: University of Washington; Other
Eligibility: Up to 3 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: Prostate Cancer
Interventions: stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1), stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2); Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Minneapolis, Minnesota + 2 more

Conditions: Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions: Avelumab, Sunitinib; Drug
Lead sponsor: Guru Sonpavde; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pain Control, Ureteral Reimplantation, Pediatrics, Intrathecal Morphine
Interventions: Intrathecal Morphine, Quadratus lumborum block; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Months to 11 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Symptom-Targeted Approach to Rehabilitation for Concussion (STAR-C)

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Treating Exacerbations of Asthma With Oral Montelukast in Children

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

TOM: Testosterone in Older Men With Sarcopenia

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

ITM vs QL for Pediatric Open Lower Abdominal Procedures